Cullinan's innovative approach and Zipalertinib's potential approval in 2026 position it as a promising biotech investment.

In light of recent federal research funding cuts, the Arthritis Foundation and CARRA each contributed an additional $100,000 to support the grant program this year. Meanwhile, demand for research ...

The diagnosis of several of them can be aided by blood tests and/or imaging. There may not be a cure, but with lifestyle ...

Senior medical experts have explained why women are more at risk of developing arthritis than men, attributing it to several ...

You might associate autoimmune conditions with symptoms like skin disease, chronic pain, and fatigue. A less-discussed ...

After years of mysterious symptoms and scores of tests by dozens of doctors, she finally saw a rheumatologist who diagnosed her with Sjögrens disease, an autoimmune disorder that is more common than ...

Vor Biopharma pivots to telitacicept with $175M funding, eyeing multi-billion potential. Risks include dilution, regulatory ...

Autoimmune disorders are sometimes viewed as separate conditions, joint pain in rheumatoid arthritis, skin lesions in ...

Intravenous belimumab plus SOC vs placebo plus SOC was not linked to an increased risk for infection among patients with SLE.

Dr. Kimberly Trotter distilled four high-impact disease clusters—gout, rheumatoid arthritis (RA), systemic lupus ...

Lay Summary Almost all patients with SLE experience joint problems and arthritis, 12% suffer permanent joint damage. The wide variability in SLE arthritis and the limitations of existing assessment ...

Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase 3 clinical trial in gMG is currently ...